bluebird bio Inc (NAS:BLUE)
$ 0.6062 0.0322 (5.61%) Market Cap: 116.84 Mil Enterprise Value: 239.70 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 25/100

bluebird bio Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 12, 2020 / 02:30PM GMT
Release Date Price: $39.99 (-1.14%)
John Lawrence Newman
Canaccord Genuity Corp., Research Division - Principal & Senior Healthcare Analyst

Welcome to the 40th Annual Canaccord Genuity Growth Conference held virtually this year. I'd like to welcome bluebird bio, who I'm sure everyone knows. Here to tell us more about the company today are the CEO, Nick Leschly; and the Chief Scientific Officer, Dr. Philip Gregory.

So Nick and Philip, welcome, and thanks very much for joining us today.

Questions & Answers

John Lawrence Newman
Canaccord Genuity Corp., Research Division - Principal & Senior Healthcare Analyst

I wonder if you could start by talking to us about the resubmission of ide-cel for relapsed/refractory multiple myeloma. It's great to see that, that's done now. Could you give us any details on the CMC portion? Or maybe just speak generally about the issues that were successfully addressed.

Nick Leschly
bluebird bio, Inc. - President, CEO & Director

Yes. Thank you. This is Nick talking, so people can recognize

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot